Antimicrobial Resistance Surveillance and Research Network | This document contains detail procedures on sample collection, transport, isolation, identification of fungi for the diagnosis of invasive fungal infections
...
and antifungal susceptibility testing of yeast
more
This study addresses part of the Terms of Reference for a scoping report ‘An analysis of approaches to laboratory capacity strengthening for drug resistant infections in low and middle income coun
...
tries’. It has been produced as a separate report because it is also very relevant for a second study ‘Supporting Surveillance Capacity for Antimicrobial Resistance: Regional Networks and Educational Resources’. This study compares antimicrobial surveillance systems in three low and middle income countries in order to describe the components of these systems and to understand which surveillance models are best suited to particular contexts. Ghana, Nigeria and Nepal were selected as study countries because they cover different continents and include one ‘fragile’ context (Nigeria). Brief information from Malawi is also included.
more
The global emergence of antimicrobial resistance (AMR) is posing a threat to human health. Putting resources into the containment of AMR – including surveillance – is one of the highest-yield investments a country can make to mitigate its impact. In 2015, WHO launched the Global Antimicrobial Re
...
sistance Surveillance System (GLASS), the first global collaborative effort to foster AMR surveillance in bacteria causing acute infections. As of December 2018, 71 countries are enrolled in GLASS. The aim of this report is to document participation efforts and outcomes across these countries, and highlight differences and constraints identified to date. This report follows on from the first GLASS Report – Early implementation 2016-17, published in January 2018, and drawing on data from GLASS first data call in 2017.
more
Internationally, there is a growing concern over antimicro-bial resistance (AMR) which is currently estimated to ac-count for more than 700,000 deaths per year worldwide. If no appropriate measures are taken to halt its pro-gress, AMR will cost approximately 10 million lives andabout US$100 trillion
...
per year by 2050. In contrast tosome other health issues, AMR is a problem that con-cerns every country irrespective of its level of incomeand development as resistant pathogens do not respect borders.Despite the threat presented by AMR, the 2014 WorldHealth Organization (WHO) and the recent O’Neill re-port describe significant gaps in surveillance, standardmethodologies and data sharing. The 2014 WHOreport identified Africa and South East Asia as the regions without established AMR surveillance systems.
Tadesseet al. BMC Infectious Diseases (2017) 17:616 DOI 10.1186/s12879-017-2713-1
more
Methicillin-resistant Staphylococcus aureus(MRSA) strainsor multidrug-resistant S.aureus, initially described in 1960s,emerged in the last decade as a cause of nosocomial infections responsible for rapidly progressive, potential fatal diseases including life-threatening pneumonia, necrotizing fascii
...
tis, endocarditis, osteomyelitis, severe sepsis, and toxinoses such as toxic shock syndrome. A multifactorial range of independent risk factors for MRSA has been reported in literature and include immunosuppression,hemodialysis, peripheral malperfusion, advanced age, extended in-hospital stays, residency in long-term care facilities (LTCFs), inadequacy of antimicrobial therapy,indwelling devices, insulin-requiring diabetes, and decubitusulcers, among others.
Hindawi Canadian Journal of Infectious Diseases and Medical Microbiology Volume 2019, Article ID 8321834, 9 pageshttps://doi.org/10.1155/2019/8321834
more
15. Euro Surveill. 2017;22(47):pii=17-00103
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
Qualitative assay for use on the cobas®6800/8800 Systems. For in vitro diagnostic use
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
Training laboratory managers, senior biologists, and technologists in quality management systems is a step towards obtaining international recognition; it is a step that all countries should take. T
...
his training toolkit is intended to provide comprehensive materials that will allow for designing and organizing training workshops for all stakeholders in health laboratory processes, from management, to administration, to bench-work laboratorians
more
This core package of materials provides a comprehensive introduction to the FAST strategy: a focused approach to stopping TB spread in congregate settings. This core package is composed of a booklet, job aids, posters, and a button which serves as a
...
visual reminder to staff and patients of the importance of this strategy in TB control. FAST can be implemented in both general and TB specific medical settings. Download the complete package from the website https://drtbnetwork.org/fast-tb-infection-control-strategy-core-package
more
Antimicrobial resistance(AMR) poses a serious threat to human, animal and environmental health. Implementing ethical practice guidelines on how to use antimicrobials effectively and
...
responsibly within the pig industry will contribute in reducing and preventing antimicrobial resistance within the pig industry of South Africa. Members of Pig Vet Society (PVS) SA hereby commit themselvesto put these guidelines into good use in order to preserve the future and effectiveness of antimicrobials. PVS aims to be the leader in prevention of antimicrobial resistance and to encourage the pig industry to work together in achieving this.
more
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
Brief instructions for the diagnostic of specimens coming from suspected plague cases and exposed contacts, including recommendations for diagnostic confirmation
Best Practice for the Care of Patients with Tuberculosis: a Guide for Low-Income CountriesThe practical aspects of TB patient care from the onset of symptoms to the completion of treatment are covered in this guide.
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa
...
and lays out urgent policy recommendations to address the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more
Manual para la primera fase de implementación